Ernexa Therapeutics To Present Preclinical Data On Gene-Modified iPS-Derived MSCs Reprogramming Immune Microenvironment In High-Grade Serous Ovarian Cancer At AACR Conference On September 20

Ernexa Therapeutics (NASDAQ:ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced preclinical data will be presented at the inaugural AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research. The oral presentation, taking place on September 20, 2025 in Denver, is titled "Gene-modified iPS-derived MSC restore a ‘Hot' immune microenvironment in high-grade serous ovarian cancer."

The presentation will highlight new preclinical findings from Ernexa's lead program, ERNA-101, a synthetic, off-the-shelf cell therapy designed to activate and regulate the immune system to recognize and attack cancer cells. These findings support the continued advancement of ERNA-101 toward clinical evaluation in ovarian cancer. The oral presentation will be made by Michael Andreeff, M.D., Ph.D., professor at The University of Texas MD Anderson Cancer Center.